Why manufacturer names matter, but should not be treated as a ranking
Manufacturers of knee replacement implants range from a small group of global orthopedic companies to regional and specialty suppliers. For patients, hospital buyers, and industry readers, the key question is not which brand is universally best. It is whether a specific implant system has the right regulatory clearance, dependable supply, surgeon familiarity, registry support, post-market surveillance, and a design suited to the clinical case.
At the time of writing in October 2026, the knee implant market is still led by large joint-replacement portfolios from Zimmer Biomet, Stryker, Johnson & Johnson MedTech through DePuy Synthes, and Smith+Nephew. Companies such as Medacta, MicroPort Orthopedics, Exactech, Aesculap, Enovis, Corin, Waldemar Link, and others compete in selected markets and procedure types. For more coverage of device categories, see our Implants section.
A knee implant is not a single product. A total knee replacement usually combines a femoral component, a tibial baseplate or tray, a polyethylene insert, and sometimes a patellar component. Partial knee, revision knee, constrained, hinged, cemented, and cementless systems may use different components, indications, and regulatory pathways. For that reason, manufacturer comparisons need to go beyond brand recognition and look at evidence, inventory depth, instrumentation, and the surgeon’s ability to use the system consistently.
Major manufacturers and commonly discussed knee systems
The table below is an industry overview, not a clinical recommendation. Product availability, indications, and naming can vary by country, hospital contract, and regulatory clearance. Patients should ask their surgeon which exact system, component configuration, and fixation method are being considered.
| Manufacturer | Examples of knee systems or related platforms | What the name usually signals in the market |
|---|---|---|
| Zimmer Biomet | Persona, NexGen, Vanguard, ROSA Knee System | One of the largest reconstructive orthopedics portfolios, with broad primary, partial, and revision knee options. |
| Stryker | Triathlon, Triathlon Cementless, Mako Total Knee | Strong association between knee implants and robotic-arm-assisted planning through the Mako platform. |
| Johnson & Johnson MedTech / DePuy Synthes | ATTUNE Knee System, VELYS digital surgery technologies | A large orthopedic portfolio currently connected to Johnson & Johnson, with a planned separation of the orthopaedics business into DePuy Synthes targeted for 2027 according to company updates. |
| Smith+Nephew | LEGION, JOURNEY II, CORI Surgical System | A major global orthopedic manufacturer with knee systems and enabling technologies used in conventional and computer-assisted workflows. |
| Medacta | GMK Primary, GMK Sphere, GMK SpheriKA, NextAR Knee | A specialist orthopedic supplier known for knee platforms that emphasize kinematic alignment, medial ball-in-socket concepts, and surgeon education programs. |
| MicroPort Orthopedics | Evolution Medial-Pivot, Advance, revision knee systems | Known for medial-pivot knee design heritage and a focused hip and knee reconstruction portfolio. |
| Exactech | Truliant, Optetrak Logic | A manufacturer still associated with knee products, but also with important recall history involving some polyethylene components and packaging, making device-lot verification especially important. |
Other manufacturers may be important in particular regions, including Aesculap, Waldemar Link, Corin, United Orthopedic, Enovis, and smaller suppliers focused on revision, custom, or regional hospital procurement channels. A complete manufacturer list depends on the country, because implant approval, hospital purchasing, and registry reporting differ by market.
How manufacturers differ in knee replacement implants
Implant design philosophy
Manufacturers differentiate knee systems through design choices such as cruciate-retaining versus posterior-stabilized options, medial-pivot geometry, constrained or hinged designs for complex instability, mobile-bearing versus fixed-bearing inserts, anatomy-focused sizing, and component shapes intended to improve fit. These claims should be read carefully. A design concept may be clinically plausible without proving superiority for every patient group.
Fixation strategy
Cemented fixation remains common in total knee arthroplasty. Cementless knee systems have grown as manufacturers introduce porous coatings, 3D-printed porous metals, and surface technologies intended to encourage bone ingrowth. A cementless option is not automatically better. Age, bone quality, activity level, surgeon experience, and registry data all matter.
Instrumentation and digital surgery
The implant is only one part of the system. Companies also compete through instruments, disposable kits, patient-specific guides, navigation, augmented reality, and robotics. Stryker’s Mako, Zimmer Biomet’s ROSA, Smith+Nephew’s CORI, and DePuy Synthes’ VELYS ecosystem show how implant manufacturers increasingly pair hardware with planning and execution tools.
AAOS American Joint Replacement Registry materials reported that robotic assistance in U.S. primary total knee arthroplasty increased over recent years and approached 16.1% in aggregate analysis for 2024. Registry authors also noted limitations in data capture and confounding, so the figure should not be read as a direct performance comparison between manufacturers.
Depth of revision and complex-case portfolios
Primary knee replacement receives most public attention, but hospital value committees also look closely at revision systems. Revision knee surgery may require stems, augments, cones, sleeves, constrained inserts, or hinged designs. Manufacturers with broad revision portfolios can be attractive to hospitals that need continuity from routine primary cases to complex failures, infection revisions, bone-loss cases, and instability cases.
What evidence should hospitals and surgeons use?
A credible manufacturer comparison usually combines several evidence layers. No single source is enough on its own.
- Regulatory status: In the United States, many knee prosthesis categories are class II devices cleared through FDA pathways such as 510(k), while certain more constrained or high-risk configurations can fall into different classifications. Clearance means the device met the relevant regulatory requirements for its pathway; it should not be read as a guarantee of long-term clinical performance.
- Registry performance: National registries can identify revision patterns that may not appear in small trials. The AAOS American Joint Replacement Registry 2025 Annual Report analyzed more than 4.4 million hip and knee procedures with data collected from 2012 through 2024 across U.S. states, the District of Columbia, and Puerto Rico. The UK National Joint Registry reported in 2026 that it had recorded more than 4.6 million procedures since April 2003 and included 143,972 knee procedures submitted for calendar year 2025.
- Peer-reviewed follow-up: Ten-year and longer survivorship data are especially useful, but they must be tied to the exact implant construct, fixation, bearing, and patient population.
- Post-market signals: Recalls, field safety notices, complaint patterns, and manufacturer corrective actions should be reviewed before procurement decisions.
- Surgeon experience: Even a well-supported system can perform poorly if the surgeon is unfamiliar with its sizing, balancing, instrumentation, or revision options.
- Hospital logistics: Sterile processing, implant availability, rep support, loaner trays, emergency revision inventory, and contract terms can affect real-world performance and cost.
For industry readers, it is important to separate market size from clinical evidence. ORTHOWORLD’s 2026 joint replacement analysis identifies Zimmer Biomet, Stryker, J&J MedTech, and Smith+Nephew as the four companies with more than $1 billion in annual joint replacement sales and estimates that these four account for 71% of global joint replacement sales. That figure describes the broader joint replacement business, not a knee-only clinical ranking. Large revenue can indicate installed base, distribution strength, and product breadth, but it does not prove that one knee implant is best for a specific patient.
Recall history and post-market surveillance cannot be ignored
Manufacturer evaluation should include what happens after launch. The FDA’s Exactech safety communications are a clear example. The agency described risks with certain Exactech joint replacement devices manufactured between 2004 and August 2021 and recalled in 2021 and 2022, including knee, ankle, and hip devices packaged in defective bags. The issue involved missing oxygen barrier layers, which could allow oxidation of polyethylene components and contribute to excessive wear, component fracture, device failure, bone loss, pain, swelling, or revision surgery.
This does not mean every Exactech implant is affected, and it does not mean a well-functioning recalled device should automatically be removed. FDA communications specifically advised that surgery is not recommended solely to remove a well-functioning Exactech device in patients without pain or symptoms. The broader lesson is practical: every implant system should be traceable by manufacturer, model, lot, and serial number, and hospitals should maintain reliable implant records for the life of the device. See also: Fixation.
Questions patients can ask about the implant manufacturer
Patients usually do not choose knee implants the way they choose consumer products. The surgeon’s training, the hospital’s approved vendor list, and the patient’s anatomy narrow the options. Even so, informed questions can improve transparency.
- Which manufacturer and exact implant system do you plan to use?
- Is the implant cemented or cementless, and why is that appropriate for my bone quality and age?
- Is this a total, partial, constrained, or revision-type knee system?
- How long have you used this system, and roughly how many cases have you performed with it?
- Does registry or published evidence support this implant in patients like me?
- Will robotic, navigated, patient-specific, or conventional instruments be used?
- How will I receive my implant card or record of manufacturer, model, and lot information?
- Has this exact component family had safety notices or recalls that are relevant to my planned surgery?
For clinicians and hospital committees, the same issues apply at a procurement level. Key checks include whether the company supports data sharing, whether implant attributes are uploaded correctly to registries, whether revision components are available promptly, and whether the supplier can sustain quality and logistics during product transitions.
What is changing in 2026?
Three trends are shaping the manufacturer landscape. First, enabling technology is becoming more tightly connected to implant choice. A hospital that adopts a robotic platform may also be committing to certain implant families, software updates, disposable workflows, and training pathways.
Second, registry data are becoming more influential. Reports from AJRR and NJR are not simple brand rankings, but they help the market move away from marketing claims and toward survivorship, revision risk, and procedural trends.
Third, corporate structure is shifting. Johnson & Johnson announced in October 2025 its intent to separate its orthopaedics business, with later 2026 company remarks indicating the planned DePuy Synthes separation remained on track for mid-2027. Such changes can affect commercial focus, sales coverage, innovation investment, and hospital contracting, although the clinical impact depends on execution rather than announcement language.
The safest editorial conclusion is cautious: the leading manufacturers of knee replacement implants are not interchangeable, but they should not be ranked by brand familiarity alone. The best-supported choice is the implant system that fits the patient, is used well by the surgeon, has appropriate regulatory status, has credible follow-up data, and can be traced and monitored after implantation.
Frequently asked questions
Which company makes the best knee replacement implant?
There is no universal best manufacturer for every patient. Implant choice depends on anatomy, diagnosis, bone quality, ligament condition, surgeon experience, available components, and evidence for the specific system. A high-volume brand is not automatically the best option for a particular knee.
How can someone find out who manufactured their knee implant?
The implant manufacturer and model are usually documented in the operative report, implant log, hospital record, or patient implant card. Patients who do not have this information can ask the hospital medical records department or the surgeon’s office for the implant sticker sheet or device identifiers.
Are robotic knee replacements made by different manufacturers?
Robotic and computer-assisted systems are often linked to specific manufacturers and implant families. For example, Mako is associated with Stryker’s knee ecosystem, ROSA with Zimmer Biomet, CORI with Smith+Nephew, and VELYS with DePuy Synthes technologies. Availability and compatible implants vary by market and hospital.
Does an FDA-cleared knee implant mean it will last longer?
No. FDA clearance or approval addresses regulatory requirements for marketing a device under a defined pathway. Longevity is assessed through clinical follow-up, registry data, revision rates, post-market surveillance, and real-world use by trained surgeons.
Should a recalled knee implant always be removed?
Not necessarily. Recall management depends on the device, symptoms, imaging, and medical risk. In the Exactech packaging issue, FDA communications advised against surgery solely to remove a well-functioning device in patients without pain or symptoms. Anyone concerned about a recall should speak with an orthopedic surgeon and verify the exact device identifiers.